168

Pertuzumab + Trastuzumab Solution for Subcutaneous Injection

Prescriber Criteria: Consultant Oncologist

Inpatient use:
Reserved for patients with:

- Early breast cancer, in combination with chemotherapy in:
  - the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence, or
  - the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
- Metastatic breast cancer, in combination with a taxane (docetaxel or paclitaxel) in adult patients with HER2-positive advanced or metastatic breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Duration of Approval:
1 year